The Pharmaceuticals Export Promotion Council of India (Pharmexcil) has suspended the membership of Haryana-based Maiden Pharmaceuticals, whose cough syrups are under the scanner following the death of 66 kids in the Gambia after they allegedly consumed it. After this suspension, the company’s exports will become ineligible for incentives under the Market Access Initiative Scheme.
Pharmexcil suspended the authorization certificate after the Pharmaceutical company failed to share details of its licensees and importers by October 7, as asked by the council.
“The council is not in receipt of any inputs/report on the adverse events and hereby state that the membership of Maiden Pharmaceuticals with Pharmexcil… is suspended with immediate effect,” the council said in a letter dated October 7, to the company.
